One To Watch
Evonik International
Company Overview
A global specialty chemicals and contract development and manufacturing organization (CDMO) that supplies advanced drug delivery technologies — including lipid nanoparticles, excipients, and oral delivery systems — to pharmaceutical and biotech clients worldwide. Evonik's Health Care business unit sits within its broader specialty chemicals portfolio and focuses on enabling partners to formulate and manufacture complex therapeutics. The company operates across more than 100 countries and ranks as the second-largest chemicals company in Germany.
Headquarters and Global Presence
Evonik Industries AG is headquartered in Essen, North Rhine-Westphalia, Germany. The company maintains a significant North American presence and, most recently, expanded its Asia-Pacific drug delivery footprint through a new facility in Yokohama, Japan, opened in April 2026 in collaboration with Higuchi Inc.
Founding and History
The company traces its origins to 1847, when chemist Theodor Goldschmidt founded Chemische Fabrik Th. Goldschmidt in Berlin. The business relocated to Essen in 1889–1890, laying the groundwork for what is today the Goldschmidtstrasse site. Evonik Industries AG emerged in its current form through a series of corporate reorganizations and is publicly listed on the Frankfurt Stock Exchange. Over the past decade, the company has systematically built out its Health Care and CDMO capabilities alongside its core specialty chemicals franchise.
Therapy Areas and Focus
Evonik's Health Care unit does not pursue its own drug approvals but enables clients across a broad therapeutic spectrum — including oncology, rare disease, and nucleic acid therapeutics — by supplying delivery materials and formulation expertise. The strategic rationale is straightforward: as biologics, RNA medicines, and targeted therapies grow in complexity, demand for sophisticated excipients and delivery vectors rises. Evonik positions itself as an ingredient and platform partner at the earliest stages of drug development, aiming to be embedded in a client's formulation long before commercial scale-up.
Technology Platforms and Modalities
Evonik's core drug delivery portfolio encompasses lipid-based systems (including lipid nanoparticles for nucleic acid delivery), EUDRAGIT polymeric excipients for oral drug delivery, and specialty lipids used in injectable formulations. Its RESOMER biodegradable polymers are widely used in controlled-release parenteral and implantable formulations. A 2025 strategic partnership with Ethris will integrate Ethris' proprietary lipidoid nanoparticle (LNP) technology into Evonik's formulation development services, strengthening its RNA delivery credentials at a time of intense industry interest in the modality.
Key Pipeline and Programs
Evonik does not advance proprietary drugs through clinical trials under its own regulatory sponsorship; its value is captured through enabling client pipelines rather than owning them. On the LNP delivery front, the Ethris collaboration announced in September 2025 will develop and commercialize a novel lipidoid nanoparticle platform specifically designed to improve nucleic acid delivery efficiency and tolerability — a capability that positions Evonik to serve mRNA vaccine and siRNA therapeutic developers. In oral drug delivery, the Yokohama laboratory opened with Higuchi in April 2026 expands Evonik's formulation development capacity in Japan, focusing on solubility enhancement and controlled-release applications using EUDRAGIT and related polymer systems. The L'Oréal/Abolis tri-party agreement signed in September 2024 illustrates how Evonik's fermentation and specialty manufacturing capabilities extend beyond pharma into adjacent life science markets.
Recent Developments
In September 2025, Evonik announced a strategic partnership with Ethris to co-develop and commercialize a lipidoid nanoparticle platform for nucleic acid delivery, adding a differentiated LNP offering to its formulation services. April 2026 saw the opening of a joint Yokohama laboratory with Higuchi Inc. to expand oral drug delivery development in the Asia-Pacific region. These moves follow the September 2024 tri-party agreement with L'Oréal and Abolis Biotechnologies to support biotech-derived ingredient discovery and scale-up.
Key Personnel
Evonik Industries AG is governed by an Executive Board that steers the company's global specialty chemicals and health care strategy. Christian Kullmann serves as Chief Executive Officer of Evonik Industries AG, leading the group's strategic transformation toward higher-margin specialty businesses. Ute Wolf holds the role of Chief Financial Officer, overseeing financial performance across the company's diversified portfolio.
Strategic Partnerships
The September 2025 partnership with Ethris represents Evonik's most targeted move into next-generation RNA delivery, combining Ethris' lipidoid nanoparticle intellectual property with Evonik's formulation development infrastructure. The April 2026 Higuchi collaboration deepens Evonik's Japanese market presence for oral delivery. The 2024 L'Oréal/Abolis tri-party agreement demonstrates a broader platform strategy that monetizes Evonik's fermentation and manufacturing scale beyond traditional pharma channels.
FAQ Section
Evonik operates as an enabling partner rather than a drug sponsor, supplying proprietary excipients, delivery polymers, and formulation development services that become embedded in clients' products from early development through commercial manufacturing. Its EUDRAGIT polymer line, RESOMER biodegradable polymers, and specialty lipids are used in hundreds of marketed products globally. Revenue is captured through material supply, CDMO services, and licensing of delivery technologies — a model that provides diversified, recurring income tied to clients' commercial success.
Lipid nanoparticles are the dominant delivery vehicle for mRNA and siRNA therapeutics — a market validated by COVID-19 vaccines and now expanding into oncology, rare disease, and infectious disease. Evonik already manufactures specialty lipids used in LNP formulations, and the Ethris partnership adds a proprietary lipidoid nanoparticle platform that can offer improved delivery efficiency. This positions Evonik to capture a larger share of the RNA drug development value chain as the modality matures.
Evonik combines deep polymer chemistry expertise — most visibly in the EUDRAGIT and RESOMER product families — with integrated formulation development services and a growing biologics delivery capability. Unlike pure CDMOs, Evonik controls the synthesis of key excipients, giving it both supply security and intellectual property leverage. Its willingness to co-develop novel platforms, as demonstrated with Ethris on LNPs and with Higuchi on oral delivery in Japan, reflects a more strategic partnership model than traditional materials suppliers offer.
The Yokohama facility, opened in April 2026, gives Evonik a dedicated Asia-Pacific development hub for oral drug delivery, an area where Japan's pharmaceutical market is particularly active. Working with Higuchi Inc., a respected Japanese pharmaceutical distribution and development company, provides Evonik with local regulatory and commercial expertise. The lab focuses on solubility enhancement and controlled-release formulation — capabilities increasingly in demand as developers tackle poorly soluble small molecules and modified-release generics.
Oncology, rare disease, and infectious disease are the primary growth drivers, largely because these areas generate the most complex small molecules and biologics requiring advanced delivery. RNA therapeutics — covering vaccines, gene silencing, and gene editing applications — represent the fastest-growing segment given the LNP demand surge. Oral drug delivery for poorly soluble compounds remains a high-volume, steady-state business underpinned by generic and specialty pharma clients using EUDRAGIT polymers.
Evonik's Health Care unit is commercially mature, supplying excipients and delivery materials to marketed products across multiple geographies — it is not an emerging business but an established segment within a €15 billion-plus enterprise. The current investment cycle is oriented toward expanding capabilities in LNP and nucleic acid delivery, where the commercial opportunity is still forming. Near-term milestones include the operational ramp-up of the Yokohama oral delivery lab and the first client programs to utilize the Ethris LNP platform under the 2025 partnership.
Key watchpoints for Evonik's health care and CDMO trajectory include:
- Commercialization progress of the Ethris LNP platform and how quickly it attracts RNA therapeutic clients
- Throughput and client wins at the new Yokohama oral delivery laboratory
- Broader pharmaceutical industry capital expenditure cycles, which directly affect CDMO demand and excipient volumes
- Competitive pressure from vertically integrated LNP suppliers and large CDMOs expanding into lipid manufacturing
- Evonik's ability to maintain pricing power on EUDRAGIT and RESOMER grades as generic excipient alternatives develop
Latest Evonik International News
Today's issue
| Headless Content Management with Blaze